Biokinetica’s Phase 1 Unit has been inspected twice by FDA!

22 November 2022

We are pleased to inform you that Biokinetica’s Phase 1 Unit has recently undergone a FDA inspection on two of our biosimilar studies.

The results demonstrated GCP compliance, and our commitment towards the highest operative quality standards of our teams. We continually strive for excellence and efficiency to deliver quality services that are tailored to your needs.